Instrument Inactif

Communiqués Nutriband Inc Other OTC

Actions

US67092M1099

Equipement, fournitures et distribution médicale

Communiqués

15/05	Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference	GL
30/04	Nutriband : Annual Report for Fiscal Year Ending January 31, 2026 (Form 10-K)	PU
22/04	Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast	GL
30/03	Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch	GL
18/03	Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica	GL
17/02	Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica	GL
17/02	Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica	GL
30/01	Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points	GL
31/12	Nutriband CEO Publishes Letter to Shareholders	GL
29/12	Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio	GL
18/12	Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration	GL
18/12	Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction	GL
18/12	Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction	AQ
28/10/25	REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch	GL
28/10/25	Nutriband Inc. (NASDAQ:NTRB) Targets the Opioid Safety Gap in a Multi-Billion-Dollar Market	AQ
28/10/25	Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch	GL
27/10/25	Nutriband Co-Founder Gareth Sheridan Returns as CEO	GL
27/10/25	Nutriband Co-Founder Gareth Sheridan Returns as CEO	AQ
10/10/25	Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch	GL
08/10/25	Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology	GL
08/10/25	Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference	GL
24/09/25	Nutriband Inc. to Present at the MicroCap Rodeo Conference	GL
12/09/25	Nutriband : Publishes Q2 Report and Announces Key FDA Meeting for AVERSA™ Fentanyl	PU
10/09/25	Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl	GL
03/09/25	Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000	GL